Tarsus Pharmaceuticals Acquires iRenix Medical To Advance IRX-101 Ocular Antiseptic, Expands Ophthalmology Pipeline With $75 Million

Tarsus Pharmaceuticals has announced the acquisition of iRenix Medical, adding IRX-101, an investigational ocular antiseptic, to its pipeline. The candidate is being developed to reduce post-procedural pain and corneal toxicity in patients undergoing intravitreal injections, a procedure commonly used to treat chronic retinal diseases.

IRX-101 is a stable aqueous chlorine dioxide solution that demonstrated promising results in the Phase 2b/3 RELIEF trial. Compared with the current standard antiseptic, povidone-iodine (Betadine®), the therapy achieved statistically significant reductions in patient pain and corneal surface damage following treatment procedures.

"With XDEMVY, we demonstrated the importance of meaningful innovation in areas of eye care that had previously been overlooked despite their significant impact on patients," said Bobby Azamian, M.D., PhD, Chief Executive Officer and Chairman of Tarsus. "We believe IRX-101 has the potential to do the same for patients with retinal disease who rely on repeated procedures to preserve their vision. By reducing the pain and ocular surface toxicity associated with current antiseptic approaches, IRX-101 has the potential to benefit both patients and physicians while also establishing an important foundation in retina as we continue building a leading eye care company."

The trial enrolled 154 patients and showed an approximately 50% reduction in post-procedural pain scores, with half of the patients receiving IRX-101 reporting no pain at all after treatment. The study also reported an approximately 25% reduction in corneal fluorescein staining, indicating less corneal surface damage compared with povidone-iodine.

“IRX-101 was developed to improve the treatment experience for patients undergoing repeated retinal procedures,” said Stephen J. Smith, M.D., Chief Executive Officer and Co-Founder of iRenix Medical. “I am incredibly proud of what the iRenix team accomplished in advancing the program into late-stage clinical development and demonstrating its potential to improve the patient experience meaningfully. We believe Tarsus is the ideal company to take IRX-101 through the next stage of development and ultimately bring it to patients. Their track record of identifying important unmet needs in eye care and successfully developing and commercialising innovative therapies gives us confidence in the future of the program.”

More than 11 million intravitreal injections are performed annually in the United States, primarily in patients with conditions such as Neovascular Age-Related Macular Degeneration, Diabetic Macular Oedema, Retinal Vein Occlusion-related Macular Oedema, and Geographic Atrophy. Because many patients require injections every few weeks, treatment-related discomfort can become a recurring burden, affecting adherence and continuity of care.

“Retina specialists have relied on the same antiseptic approach for decades – not because it's ideal, but because there simply hasn't been a better alternative,” said David M. Brown, M.D., Chief Medical Officer, Retina Consultants of America. “Patients regularly tell us the burning and irritation after treatment are among the most difficult parts of repeated injections. Based on the data generated to date, IRX-101 has the potential to meaningfully improve that experience while maintaining the antiseptic activity physicians depend on. That combination is what makes us so excited about IRX-101.”

Based on discussions with the U.S. Food and Drug Administration, Tarsus plans to begin a Phase 3 trial evaluating the safety and tolerability of IRX-101 in the first half of 2027, with results expected in 2028. The acquisition includes an upfront payment of approximately $75 million, split equally between cash and Tarsus stock, as well as potential regulatory and commercial milestone payments of up to $490 million.